Pulmonary Arterial Hypertension Pipeline Comparative Analysis Review H2 2015

1. Pulmonary Arterial Hypertension - Pipeline Review, H2 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 23-Sep-2015 No. of pages: 173 Single User License: US $2000 Browse more Reports on Pharmaceuticals at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

2. Pulmonary Arterial Hypertension - Pipeline Review, H2 2015 This report provides comprehensive information on the therapeutic development for Pulmonary Arterial Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

3. Pulmonary Arterial Hypertension - Pipeline Review, H2 2015 Companies Discussed/Mentioned in this Research: APT Therapeutics, Inc., Arena Pharmaceuticals, Inc., Asahi Kasei Pharma Corp., Ascendis Pharma A/S, Bial - Portela & Ca, S.A., Cardioxyl Pharmaceuticals, Inc., Carolus Therapeutics, Inc., Celsion Corporation, Corridor Pharmaceuticals Inc., Cytokinetics, Inc., Eli Lilly and Company, Gilead Sciences, Inc., Insmed Incorporated, Lacer, S.A., LTT Bio-Pharma Co., Ltd., Mezzion Pharma Co. Ltd., miRagen Therapeutics, Inc., Nippon Shinyaku Co., Ltd., Novartis AG, Peloton Therapeutics, Inc., PharmaIN Corporation, PhaseBio Pharmaceuticals, Inc., Pluristem Therapeutics Inc., Proteo and more… Drugs Profile Discussed in this Research: (allopurinol + apocynin), Antibody for Cancer and PAH, Antibody for Pulmonary Arterial Hypertension, APT-102, bardoxolone methyl, beraprost sodium ER, beraprost sodium SR, BIA-51058, CT-2009, Drugs to Antagonize Notch Receptor 3 for Pulmonary Arterial Hypertension, fasudil, GS-4997, imatinibmesylate, INS-1009, LA-419, lisuride, MFC-001, MFC-002, Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension, Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension, Oligonucleotide to Inhibit miR-145 for PAH, PB-1046, PB-1120, Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension and more…. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

4. Pulmonary Arterial Hypertension - Pipeline Review, H2 2015 Scope For Pulmonary Arterial Hypertension - Pipeline Review, H2 2015 • The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Pulmonary Arterial Hypertension and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Pulmonary Arterial Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • A detailed assessment of monotherapy and combination therapy pipeline projects ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

5. Pulmonary Arterial Hypertension - Pipeline Review, H2 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

6. Pulmonary Arterial Hypertension - Pipeline Review, H2 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441